September 26, 2002.
New Australian diagnostic technology that could save thousands of people from blindness is expected to gain American Food and Drug Authority (FDA) approval soon.
Developed by Sydney-based company ObjectiVision Pty Ltd, the AccuMap diagnostic technology can detect diseases like glaucoma and other central nervous system conditions including multiple sclerosis. It maps abnormalities in a patient's vision by measuring tiny electronic signals passing between the eye and the brain.
Submissions were made to the FDA in July this year, after AccuMap was approved by Australian authorities last October.
Chief executive officer John Newton said ObjectiVision was focussed on developing relationships with Australian and overseas researchers.
He said work was underway with the Australian National University to develop an improved reporting algorithm which will reduce test time and improve accuracy with clinical trials expected to begin this year.
"By using this new and far less stressful technology Ophthalmologists can now record what the brain actually sees as opposed to what the patient thinks they can see," Mr Newton said.
Mr Newton said during previous clinical trials in the United Kingdom and Australia, AccuMap had diagnosed sight abnormalities in around 95 per cent of cases.
Initially funded by a National Health and Medical Research Council grant, AccuMap commenced commercial development in 1999 posting its first sales in May this year.
A $2 million cash injection from the Perth-based Medical Corporation and $1.3 million in grants from the NSW Department of State and Regional Development had helped the company reach this goal.
Go to ...
Top of Page.
List of Categories.
Blind World Website
Designed and Maintained by:
All Rights Reserved.